Lead Product(s) : Clofutriben
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sparrow Completes Phase 2 and Gets Orphan Status for Clofutriben in Cushing’s
Details : SPI-62 (clofutriben) is a potent and selective HSD-1 inhibitor. Currently, it is being evaluated for the treatment of endogenous Cushing’s syndrome.
Brand Name : SPI-62
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 28, 2024
Lead Product(s) : Clofutriben
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?